Profile data is unavailable for this security.
About the company
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-87.98m
- Incorporated2019
- Employees163.00
- LocationLianBio103 Carnegie Center DriveSuite 309, Suite 215PRINCETON 08540United StatesUSA
- Phone+1 (609) 486-2308
- Websitehttps://www.lianbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuo Therapeutics Inc | 782.01k | -3.02m | 33.83m | -- | -- | 99.50 | -- | 43.26 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 34.10m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Rapid Micro Biosystems Inc | 23.10m | -51.90m | 34.29m | 193.00 | -- | 0.3231 | -- | 1.48 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 34.44m | -- | -- | 3.31 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 34.52m | 8.00 | -- | 2.92 | -- | 10.39 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 34.93m | 6.00 | -- | 453.00 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 35.50m | 163.00 | -- | 0.174 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 35.51m | 55.00 | -- | 1.19 | -- | 2.10 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Surrozen Inc | 0.00 | -37.58m | 35.86m | 42.00 | -- | 0.7838 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 35.87m | 32.00 | -- | 0.4836 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Janone Inc | 0.00 | -18.58m | 35.95m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
| OncoCyte Corp | 1.38m | -40.66m | 36.62m | 43.00 | -- | 1.96 | -- | 26.50 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Cyclo Therapeutics Inc | 1.13m | -19.39m | 36.63m | 8.00 | -- | 60.04 | -- | 32.52 | -1.03 | -1.03 | 0.0557 | 0.0213 | 0.2001 | 0.4155 | 11.12 | 140,806.30 | -344.43 | -132.22 | -17,225.46 | -215.17 | 91.02 | 90.37 | -1,721.63 | -1,114.04 | 0.968 | -- | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Fortress Biotech Inc | 85.11m | -62.86m | 36.65m | 186.00 | -- | 1.55 | -- | 0.4306 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 36.90m | 10.00 | -- | 0.4357 | -- | 87.24 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 37.01m | 17.00 | -- | 1.54 | -- | 7.86 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Data as of Jun 03 2024. Currency figures normalised to LianBio's reporting currency: US Dollar USD
54.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 29 Feb 2024 | 57.56m | 53.26% |
| SCHF (GPE) LLCas of 30 Sep 2023 | 937.50k | 0.87% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 615.19k | 0.57% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 125.46k | 0.12% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 14.62k | 0.01% |
| FNY Capital Management LPas of 31 Mar 2024 | 13.80k | 0.01% |
| JGP Gest�o de Recursos Ltda.as of 31 Jan 2024 | 530.00 | 0.00% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
| Anson Funds Management LPas of 31 Mar 2024 | 0.00 | 0.00% |
| Casdin Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
